# Marty Makary

Type: Person

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/marty-makary
Canonical HTML page: https://getlegalbrief.com/entity/marty-makary

## Timeline

- **2026-08-19**: Trump announces Overton nomination — Trump posts the nomination on social media, calling Overton a ROCKSTAR and quoting HHS Secretary Kennedy: Heidi is ALWAYS RIGHT.
- **2026-08-18**: Administration still interviewing FDA candidates — A senior administration official says the search remains open the day before the announcement; Brad Wenstrup and Kyle Diamantas have already declined.
- **2026-08-10**: Trump signs childhood-vaccination executive order — Overton stands at Trump's side and urges blue states to adopt the administration's gold standard recommendations, which many physicians say lack scientific support.
- **2026-05**: Marty Makary resigns as FDA commissioner — Makary steps down after clashes with the White House, creating the vacancy Overton would fill.
- **2026-03-11**: Document Request — Expected date for formal requests for internal FDA communications regarding DMD drug applications.
- **2026-03-10**: Investigation Announced — Sen. Ron Johnson publicly declares a formal inquiry into the FDA's rare disease drug approval process.
- **2026-03-10**: Commissioner Consultation — Johnson speaks with FDA Commissioner Marty Makary to discuss specific drug rejections and agency policy.

## Recent coverage (2 stories)

### Heidi Overton, Trump's 3rd FDA Pick, Faces Senate Confirmation Fight
2026-08-19 18:18:12 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Trump's nomination of Heidi Overton to lead the FDA sets up a high-stakes Senate confirmation and a new era of administrative rulemaking on vaccines and food safety. Regulatory lawyers are watching the precedent set by the narrow CDC confirmation of Erica Schwartz and the legal vulnerabilities in the administration's childhood-vaccination executive order.
Full story: https://getlegalbrief.com/story/heidi-overton-fda-nomination-senate-confirmation-legal

### Senator Johnson Launches Investigation into FDA Rare Disease Drug Denials
2026-03-10 22:17:42 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA’s regulatory processes regarding the rejection of biologic therapies for Duchenne muscular dystrophy and other rare diseases. The probe follows high-level discussions with FDA Commissioner Marty Makary and focuses on whether the agency's evidentiary standards are too restrictive for life-threatening conditions.
Full story: https://getlegalbrief.com/story/senator-johnson-fda-rare-disease-investigation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.